Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Oncorus logo — Driving Innovation to Transform Outcomes for Cancer Patients

Oncorus

Driving Innovation to Transform Outcomes for Cancer Patients

Founded 2015 United States Andover, United States 6 employees Post-IPO Debt Total: $217.50M Biotechnology, Health and Wellness

General Information

Company Name Oncorus
Founded Year 2015
Location United States Andover, United States
Founders / Decision Makers
Team member Team member
Employees 6
Industries Biotechnology, Health and Wellness
Funding Stage Post-IPO Debt
Social

BounceWatch is an independent company data service, not affiliated with Oncorus. To contact Oncorus, visit oncorus.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

About Oncorus

Oncorus is a biotechnology startup founded in 2015 and headquartered in the United States. The company's slogan "Driving Innovation to Transform Outcomes for Cancer Patients" reflects their core mission. Oncorus focuses on harnessing the potential of IV-administered, self-amplifying RNA medicines to revolutionize cancer treatment. They aim to leverage this modality to safely and effectively target and destroy tumor cells while simultaneously stimulating multiple aspects of the immune system to enhance the body's ability to combat cancer. In their most recent investment round, Oncorus secured a significant $20.00M in a Post-IPO Debt investment on 05 April 2022. The investment was facilitated by K2 HealthVentures, indicating the confidence that notable investors have in the company's innovative approach and potential for disrupting the field of cancer treatment.

Taxonomy: cancer treatment, immunotherapy, RNA medicines, oncology, drug development, innovation, investor relations, clinical research, philanthropy

Funding Rounds & Investors (5)

View All
Funding Stage Amount Investors Lead Investors Date
Post IPO Debt $20.00M 1
K2 HealthVentures
K2 HealthVentures
05 Apr 2022
Post IPO Equity $57.00M -
12 Feb 2021
Series B $79.50M 9
Celgene Cowen Digital Perceptive Advisors
Celgene, Cowen Digital +7
21 Aug 2019
Series A £4.00M -
16 Dec 2016
Series A $57.00M -
19 Jul 2016

Oncorus Alternatives & Competitors

View All Alternatives
Oncorus vs
VAXIMM AG
VAXIMM AG Switzerland

Developing innovative oral T-cell immunotherapies to treat cancer patients

Grant
4 employees
Biotechnology, Health and Wellness
Oncorus vs
Checkmate Pharmaceuticals
Checkmate Pharmaceuticals

Pioneering advanced immunotherapies to amplify cancer treatment options and improve patient outcomes...

Series C
11-50 employees
Biotechnology, Health and Wellness
Oncorus vs
Tango Therapeutics
Tango Therapeutics United States

Targeting tumor suppressor loss to unmask vulnerabilities for the next generation of precision medic...

Post-IPO Equity
157 employees
Biotechnology, Health Care
View all alternatives

FAQ About Oncorus

Driving Innovation to Transform Outcomes for Cancer Patients
Oncorus was founded in 2015.
Oncorus is headquartered in Andover, United States.
Oncorus operates in Biotechnology and Health and Wellness. Its work centres on cancer treatment, immunotherapy, RNA medicines and oncology.
Oncorus has approximately 6 employees.
Oncorus has completed 5 funding rounds, raising a total of $217.50M. The latest funding stage is Post-IPO Debt.
Top alternatives and competitors to Oncorus include VAXIMM AG, Checkmate Pharmaceuticals, Tango Therapeutics, ViraTherapeutics GmbH, NeoPhore Ltd. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Oncorus and VAXIMM AG are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Oncorus, https://bouncewatch.com/company/oncorus, updated 2 December 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes